Compile Data Set for Download or QSAR
Report error Found 62 Enz. Inhib. hit(s) with all data for entry = 11453
TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034868((2S,4R)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamin...)
Affinity DataIC50: 5nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034865((2S,4S)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamin...)
Affinity DataIC50: 27nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM617417(US20230285340, Compound 21e)
Affinity DataIC50: 90nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034843((2R,4S)-5-Biphenyl-4-yl-4-(2-carboxy-acetylamino)-...)
Affinity DataIC50: 92nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034842((2R,4S)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamin...)
Affinity DataIC50: 190nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034857((2R,4S)-5-Biphenyl-4-yl-4-(5-carboxy-pentanoylamin...)
Affinity DataIC50: 324nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034846((2R,4R)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamin...)
Affinity DataIC50: 700nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US11547687, Example 2A | US11547687, Compound Exam...)
Affinity DataKi:  0.200nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582847(US11547687, Comparative Compound I | US20230285340...)
Affinity DataKi:  0.316nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582848(US11547687, Comparative Compound J | US20230285340...)
Affinity DataKi:  0.501nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM617465(US20230285340, Example 5A)
Affinity DataKi:  0.631nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298288(US11547687, Example 2H | US10123984, Example 2H | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458421(US10744104, Example 14A | US11547687, Example 14A ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458416(US10744104, Example 11-2 | US20230285340, Example ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582844(US11547687, Comparative Compound G | US20230285340...)
Affinity DataKi:  1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298308(US10123984, Example 8-3 | US10744104, Example 8-3 ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298307(US10123984, Example 8-2 | US10744104, Example 8-2 ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458409(US10744104, Example 7B | US11547687, Example 8-3 |...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298305(US11547687, Compound Example 5A | US10123984, Exam...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298304(US10123984, Example 5-17 | US20230285340, Example ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM617438(US20230285340, Example 5-15)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458405(US10744104, Example 5-14 | US20230285340, Example ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298301(US10123984, Example 5-13 | US20230285340, Example ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458402(US10744104, Example 5-5 | US20230285340, Example 5...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM617433(US20230285340, Example 5-1)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298286(US11547687, Example 2F | US10744104, Example 2F | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458399(US10744104, Example 3D | US20230285340, Example 3D)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298295(US20230285340, Example 3A | US10123984, Example 3D...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298294(US11547687, Example 2V | US10744104, Example 2V | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298293(US11547687, Example 2U | US10744104, Example 2U | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298292(US10123984, Example 2T | US10744104, Example 2T | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298300(US10123984, Example 5-9 | US20230285340, Example 5...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298291(US10123984, Example 2N | US11547687, Example 2N | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US11547687, Example 2A | US11547687, Compound Exam...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582845(US11547687, Comparative Compound H | US20230285340...)
Affinity DataKi:  2.51nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US11547687, Example 2A | US11547687, Compound Exam...)
Affinity DataKi:  3.98nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298326(US10123984, Example 16 | US10744104, Example 16 | ...)
Affinity DataKi:  5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458423(US10744104, Example 14F | US11547687, Example 14F ...)
Affinity DataKi:  5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298322(US10123984, Example 14A | US10123984, Example 14F ...)
Affinity DataKi:  5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298315(US11547687, Example 11-1 | US10744104, Example 10 ...)
Affinity DataKi:  5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298321(US10123984, Example 13 | (R)-3-[N-(3′-Chloro...)
Affinity DataKi:  5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298319(US10123984, Example 11-4 | US10744104, Example 11-...)
Affinity DataKi:  5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298309(US10123984, Example 8-4 | US20230285340, Example 8...)
Affinity DataKi:  5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM617445(US20230285340, Example 8-5)
Affinity DataKi:  5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298297(US10123984, Example 4 | (2R,4R)-5-(3-Chlorobipheny...)
Affinity DataKi:  5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298312(US10123984, Example 9A | US10744104, Example 9A | ...)
Affinity DataKi:  5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298289(US10744104, Example 2I | US11547687, Example 2I | ...)
Affinity DataKi:  5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298287(US11547687, Example 2G | US10744104, Example 2G | ...)
Affinity DataKi:  5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298316(US10123984, Example 11-1 | US10744104, Example 11-...)
Affinity DataKi:  5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582724(US11547687, Comparative Compound A | US20230285340...)
Affinity DataKi:  6.31nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 62 total ) | Next | Last >>
Jump to: